MARKET

TVTX

TVTX

Travere Therapeutics Inc
NASDAQ
28.18
-0.09
-0.32%
After Hours: 28.48 +0.3 +1.06% 17:58 03/04 EST
OPEN
28.44
PREV CLOSE
28.27
HIGH
28.59
LOW
27.85
VOLUME
1.48M
TURNOVER
--
52 WEEK HIGH
42.13
52 WEEK LOW
12.91
MARKET CAP
2.60B
P/E (TTM)
-98.3939
1D
5D
1M
3M
1Y
5Y
1D
Travere Therapeutics (TVTX) Gets a Buy from Evercore ISI
TipRanks · 1d ago
Weekly Report: what happened at TVTX last week (0223-0227)?
Weekly Report · 2d ago
Ligand Pharmaceuticals Q4 revenue rises 39% on royalty growth
Reuters · 6d ago
Travere Therapeutics CEO Eric M. Dube Disposes of Common Shares
Reuters · 02/24 21:05
Travere Therapeutics: FILSPARI Drives Revenue, FSGS PDUFA Looms
Seeking Alpha · 02/24 12:39
Analysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY), UnitedHealth (UNH) and Travere Therapeutics (TVTX)
TipRanks · 02/23 17:10
Analysts Are Bullish on These Healthcare Stocks: MiMedx Group (MDXG), Ufp Technologies (UFPT)
TipRanks · 02/23 15:20
Analysts Are Bullish on Top Healthcare Stocks: Travere Therapeutics (TVTX), Insmed (INSM)
TipRanks · 02/23 14:30
More
About TVTX
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

Webull offers Travere Therapeutics Inc stock information, including NASDAQ: TVTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TVTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TVTX stock methods without spending real money on the virtual paper trading platform.